Publication Name	World Journal of Biological Chemistry
Manuscript ID	104535
Country	Oman

Received	2024-12-31 03:45
Peer-Review Started	2024-12-31 03:45
To Make the First Decision
Return for Revision	2025-02-14 09:18
Revised	2025-02-23 08:02
Second Decision	2025-03-03 02:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-03-04 12:32
Articles in Press	2025-03-04 12:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-03-05 05:46
Publish the Manuscript Online	2025-03-05 09:35

ISSN	1949-8454 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Minireviews
Article Title	Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction
Manuscript Source	Invited Manuscript
All Author List	Samira Farhadi, Saeed Mohammadi, Abdulaziz Y AlKindi and Issa S Al-Amri
Funding Agency and Grant Number
Corresponding Author	Issa S Al-Amri, Associate Professor, PhD, Department of Biological Sciences and Chemistry, College of Arts and Sciences,, University of Nizwa, P.O. Box 33, Nizwa 616, Ad Dākhilīyah, Oman. issa.alamri@unizwa.edu.om
Key Words	Alcohol-associated liver disease; Elafibranor; PPARα/PPARδ agonist; Macrophages; Liver fibrosis; Inflammatory responses
Core Tip	Macrophages play a central role in the progression of alcohol-associated liver disease (ALD), from initial liver injury to advanced stages like cirrhosis. Elafibranor (EFN), a dual PPARα/δ agonist, offers a promising therapeutic approach by reducing liver fibrosis, inhibiting macrophage activation, and suppressing TLR4/NF-κB inflammatory pathways. Additionally, EFN strengthens intestinal barrier function, addressing key drivers of ALD. With its dual anti-inflammatory and fibrosis-reducing effects, EFN holds potential for ALD and other liver diseases characterized by chronic inflammation and fibrosis. Further research is needed to validate its clinical applications.
Publish Date	2025-03-05 09:35
Citation	<p>Farhadi S, Mohammadi S, AlKindi AY, Al-Amri IS. Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. <i>World J Biol Chem</i> 2025; 16(1): 104535</p>
URL	https://www.wjgnet.com/1949-8454/full/v16/i1/104535.htm
DOI	https://dx.doi.org/10.4331/wjbc.v16.i1.104535

Full Article (PDF)	WJBC-16-104535-with-cover.pdf
Manuscript File	104535_Auto_Edited_033226.docx
Answering Reviewers	104535-answering-reviewers.pdf
Audio Core Tip	104535-audio.ogg
Conflict-of-Interest Disclosure Form	104535-conflict-of-interest-statement.pdf
Copyright License Agreement	104535-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	104535-non-native-speakers.pdf
Peer-review Report	104535-peer-reviews.pdf
Scientific Misconduct Check	104535-scientific-misconduct-check.png
Scientific Editor Work List	104535-scientific-editor-work-list.pdf
CrossCheck Report	104535-crosscheck-report.pdf